




Edition: BP 2025 (Ph. Eur. 11.6 update)

Escitalopram

[General Notices](#)

(Ph. Eur. monograph 2758)



$C_{20}H_{21}FN_2O$ 324.4 128196-01-0

Action and use

Selective serotonin reuptake inhibitor; antidepressant.

Ph Eur

DEFINITION

(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile.

Content

99.0 per cent to 101.0 per cent (anhydrous substance).

CHARACTERS

Appearance

White or yellowish, crystalline powder.

Solubility

Practically insoluble in water, freely soluble in anhydrous ethanol and in toluene.

IDENTIFICATION

A. Infrared absorption spectrophotometry ([2.2.24](#)).

Comparison [escitalopram CRS](#).

TESTS

Related substances

Liquid chromatography (2.2.29).

Buffer solution Dissolve 3.4 g of [potassium dihydrogen phosphate R](#) in 900 mL of [water R](#); adjust to pH 3.0 with [phosphoric acid R](#) and dilute to 1000 mL with [water R](#).

Test solution Dissolve 25 mg of the substance to be examined in mobile phase A and dilute to 50.0 mL with mobile phase A.

Reference solution (a) Dissolve 5 mg of [escitalopram for system suitability CRS](#) (containing impurity D) in mobile phase A and dilute to 10.0 mL with mobile phase A.

Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with mobile phase A.

Column:

- *size:* $l = 0.25\text{ m}$, $\varnothing = 4.6\text{ mm}$;
- *stationary phase:* [end-capped octadecylsilyl silica gel for chromatography R](#) (5 μm);
- *temperature:* 45 °C.

Mobile phase:

- *mobile phase A:* [acetonitrile R](#), buffer solution (10:90 V/V);
- *mobile phase B:* buffer solution, [acetonitrile R](#) (35:65 V/V);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)	Flow rate (mL/min)
0 - 2	95	5	1.0
2 - 37	95 → 65	5 → 35	1.0
37 - 47	65 → 0	35 → 100	1.0
47 - 62	0	100	2.0

Detection Spectrophotometer at 237 nm and at 254 nm.

Injection 20 μL .

Identification of impurities Use the chromatogram supplied with [escitalopram for system suitability CRS](#) and the chromatogram obtained with reference solution (a) to identify the peak due to impurity D.

Relative retention With reference to escitalopram (retention time = about 38 min): impurity D = about 0.98.

System suitability Reference solution (a) at 237 nm:

- *peak-to-valley ratio:* minimum 5.0, where H_p = height above the baseline of the peak due to impurity D and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to escitalopram.

Calculation of percentage contents:

- for each impurity, use the concentration of escitalopram in reference solution (b) at 237 nm.

Limits:

- *unspecified impurities at 237 nm and at 254 nm:* for each impurity, maximum 0.10 per cent;
- *total at 237 nm:* maximum 0.5 per cent;

Enantiomeric purity

Liquid chromatography ([2.2.29](#)): use the normalisation procedure.

Test solution Dissolve 25.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.

Reference solution (a) Dissolve 5.0 mg of [citalopram hydrobromide CRS](#) (containing equal amounts of impurity K and escitalopram) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.

Reference solution (b) Dilute 1.0 mL of reference solution (a) to 50.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

Column:

— **size:** $l = 0.15$ m, $\varnothing = 4.6$ mm;

— **stationary phase:** [protein derivative of silica gel for chiral separation R](#) (5 μ m);

— **temperature:** 30 °C.

Mobile phase [acetonitrile R](#), [0.05 M phosphate buffer solution pH 7.0 R](#) (15:85 V/V).

Flow rate 0.6 mL/min.

Detection Spectrophotometer at 240 nm.

Injection 15 μ L.

Run time Twice the retention time of escitalopram.

Identification of impurities Use the chromatogram obtained with reference solution (a) to identify the peak due to impurity K.

Relative retention With reference to escitalopram (retention time = about 11 min): impurity K = about 1.2.

System suitability Reference solution (a):

— **resolution:** minimum 1.3 between the peaks due to escitalopram and impurity K;

— **symmetry factor:** maximum 4.0 for the peak due to escitalopram; maximum 4.0 for the peak due to impurity K.

Limits:

— **impurity K:** maximum 2.0 per cent;

— **reporting threshold:** 0.10 per cent (reference solution (b)).

[Water \(2.5.12\)](#)

Maximum 0.2 per cent, determined on 0.500 g.

[Sulfated ash \(2.4.14\)](#)

Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.

ASSAY


Dissolve 0.300 g in a mixture of 5.0 mL of [acetic anhydride R](#) and 75 mL of [glacial acetic acid R](#). Titrate with [0.1 M perchloric acid](#), determining the end-point potentiometrically ([2.2.20](#)).

1 mL of [0.1 M perchloric acid](#) is equivalent to 32.44 mg of $C_{20}H_{21}FN_2O$.


IMPURITIES

Specified impurities K.


Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph [Substances for pharmaceutical use \(2034\)](#). It is therefore not necessary to identify these impurities for demonstration of compliance. See also [5.10. Control of impurities in substances for pharmaceutical use](#)) A, B, C, D, E, F, G, H, I, J, L, M.




A. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxamide,




B. mixture of (1RS,3RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile and (1RS,3SR)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,




C. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-oxo-1,3-dihydro-2-benzofuran-5-carbonitrile,




D. (1RS)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3-dihydro-2-benzofuran-5-carbonitrile,




E. (4*RS*)-4-[4-cyano-2-(hydroxymethyl)phenyl]-4-(4-fluorophenyl)-4-hydroxy-*N,N*-dimethylbutan-1-aminium,




F. (1*RS*)-1-[3-(dimethylamino)propyl]-1-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,




G. 4-(dimethylamino)-1-[(1*RS*)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-yl]butan-1-one,




H. 3-[(1*RS*)-5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl]-*N,N*-dimethylpropan-1-amine *N*-oxide,




I. 4-[(1*Z*)-4-(dimethylamino)-1-(4-fluorophenyl)but-1-en-1-yl]-3-(hydroxymethyl)benzonitrile,




J. 4-methylbenzenesulfonic acid (*p*-toluenesulfonic acid),



K. (1*R*)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile,



L. (1*RS*)-1-[3-(dimethylamino)propyl]-1-phenyl-1,3-dihydro-2-benzofuran-5-carbonitrile,



M. (1*RS*)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxylic acid.

Ph Eur